Infection is a common cause of death in the first year after diagnosis with lower-risk myelodysplastic syndromes, data suggest.

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

The risk of cardiotoxicity may vary across CDK4/6 inhibitors, according to a study of patients with breast cancer published in the Journal of the National Comprehensive Cancer Network.

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.